Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • WCLC 2025

World Conference on Lung Cancer (WCLC) 2025

September 06 - 09, 2025

  1. All
  2. Datopotmab deruxtecan
  3. Durvalumab
  4. Osimertinib
  5. Rilvegostomig
  6. Savolitinib
  7. Trastuzumab Deruxtecan
  8. Volrustomig

PPT

Intracranial Efficacy of Datopotamab Deruxtecan (Dato DXd) in Patients With Advanced/metastatic NSCLC in TROPION-Lung01

PPT

Patterns of Progression and Recurrence with Perioperative Durvalumab in Patients with Resectable NSCLC from AEGEAN

PPT

Detection of ctDNA Prior to Neoadjuvant Osimertinib Treatment Correlates With Decreased EFS in EGFR-Mutated NSCLC

PPT

Early Treatment Discontinuation of Osimertinib in the Adjuvant Setting: Insights From the ADAURA Study

PDF

Treatment Patterns and Clinical Outcomes in South Korean Patients With Unresectable Stage III EGFRm NSCLC Undergoing CRT

PDF

Stereotactic Body Radiation Therapy for Medically Inoperable Stage I/II EGFRm NSCLC: Global, Multicenter, Retrospective Study

PDF

Real-World (RW) Study of Biomarker Testing Patterns Among Patients With Early-Stage Resected NSCLC in the United States

PPT

First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival

PPT

First-Line Osimertinib ± Platinum-Pemetrexed in EGFR-Mutated Advanced NSCLC: FLAURA2 Clinical Outcomes by EGFRm Subtype

PPT

First-Line Osimertinib ± Platinum-Pemetrexed Chemotherapy for EGFR-Mutated Advanced NSCLC: FLAURA2 Non-Asian Country Cohort

PPT

COMPEL: Osimertinib + Platinum-Based Chemotherapy in Patients With EGFRm Advanced NSCLC and Progression on 1L Osimertinib

PDF

A Phase 3, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for First-line Treatment of Patients with Metastatic Squamous Non-small-cell Lung Cancer Whose Tumors Express PD-L1

PPT

Rilvegostomig enhances ex vivo immune activation of patient resected NSCLC tumors to greater levels than clinically approved PDx monotherapies or combinations of anti-PD1 and anti-TIGIT bivalent antibodies

PPT

Osimertinib + Savolitinib in EGFRm Advanced NSCLC With MET Overexp And/Or Amp Post-Progression on Osimertinib: SAVANNAH PROs

PPT

SAVANNAH: Biomarker Concordance and Acquired Resistance in Patients with EGFRm MET-OverExp and / or Amp NSCLC

PPT

Frontline Treatment Duration in MET-Amplified NSCLC After Third-Generation Egfr-TKI Failure: SACHI Study Insights

PPT

Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients With or Without Prior Immunotherapy

PDF

Trastuzumab Deruxtecan in Chinese Patients With Pretreated HER2-mutant Non-small cell Lung Cancer: DESTINY-Lung05 Results

PDF

Trastuzumab Deruxtecan + Pembrolizumab as First-line Treatment in HER2-overexpressing, PD-L1 TPS <50% NSCLC (DESTINY-Lung06)

PDF

Concordance of HER2 Protein Overexpression by IHC and ERBB2 Gene Amplification by NGS in Lung Cancer

PDF

Phase 3 eVOLVE-Lung02 Trial of Volrustomig + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic NSCLC with PD-L1 TC <50%

PPT

Intracranial Efficacy of Datopotamab Deruxtecan (Dato DXd) in Patients With Advanced/metastatic NSCLC in TROPION-Lung01

PPT

Patterns of Progression and Recurrence with Perioperative Durvalumab in Patients with Resectable NSCLC from AEGEAN

PPT

Detection of ctDNA Prior to Neoadjuvant Osimertinib Treatment Correlates With Decreased EFS in EGFR-Mutated NSCLC

PPT

Early Treatment Discontinuation of Osimertinib in the Adjuvant Setting: Insights From the ADAURA Study

PDF

Treatment Patterns and Clinical Outcomes in South Korean Patients With Unresectable Stage III EGFRm NSCLC Undergoing CRT

PDF

Stereotactic Body Radiation Therapy for Medically Inoperable Stage I/II EGFRm NSCLC: Global, Multicenter, Retrospective Study

PDF

Real-World (RW) Study of Biomarker Testing Patterns Among Patients With Early-Stage Resected NSCLC in the United States

PPT

First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival

PPT

First-Line Osimertinib ± Platinum-Pemetrexed in EGFR-Mutated Advanced NSCLC: FLAURA2 Clinical Outcomes by EGFRm Subtype

PPT

First-Line Osimertinib ± Platinum-Pemetrexed Chemotherapy for EGFR-Mutated Advanced NSCLC: FLAURA2 Non-Asian Country Cohort

PPT

COMPEL: Osimertinib + Platinum-Based Chemotherapy in Patients With EGFRm Advanced NSCLC and Progression on 1L Osimertinib

PDF

A Phase 3, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for First-line Treatment of Patients with Metastatic Squamous Non-small-cell Lung Cancer Whose Tumors Express PD-L1

PPT

Rilvegostomig enhances ex vivo immune activation of patient resected NSCLC tumors to greater levels than clinically approved PDx monotherapies or combinations of anti-PD1 and anti-TIGIT bivalent antibodies

PPT

Osimertinib + Savolitinib in EGFRm Advanced NSCLC With MET Overexp And/Or Amp Post-Progression on Osimertinib: SAVANNAH PROs

PPT

SAVANNAH: Biomarker Concordance and Acquired Resistance in Patients with EGFRm MET-OverExp and / or Amp NSCLC

PPT

Frontline Treatment Duration in MET-Amplified NSCLC After Third-Generation Egfr-TKI Failure: SACHI Study Insights

PPT

Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients With or Without Prior Immunotherapy

PDF

Trastuzumab Deruxtecan in Chinese Patients With Pretreated HER2-mutant Non-small cell Lung Cancer: DESTINY-Lung05 Results

PDF

Trastuzumab Deruxtecan + Pembrolizumab as First-line Treatment in HER2-overexpressing, PD-L1 TPS <50% NSCLC (DESTINY-Lung06)

PDF

Concordance of HER2 Protein Overexpression by IHC and ERBB2 Gene Amplification by NGS in Lung Cancer

PDF

Phase 3 eVOLVE-Lung02 Trial of Volrustomig + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic NSCLC with PD-L1 TC <50%

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States